3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
79
Carcinoma, Renal Cell
36
Neoplasms
35
Liver Neoplasms
22
Carcinoma, Non-Small-Cell Lung
7
Carcinoma
7
Neoplasm Metastasis
6
Melanoma
5
Thyroid Neoplasms
4
Kidney Neoplasms
4
Breast Neoplasms
3
Financial Stress
2
Vaccinia
1
Stomach Neoplasms
1
Patient Preference
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoma
1
Lung Neoplasms
1
Liver Diseases
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Insulin-Like Growth Factor I, Resistance To
1
Hypophosphatemia
1
Hepatitis C
1
Hepatitis B
1
Glioblastoma
1
Digestive System Neoplasms
1
Interventions
pembrolizumab
2
Docetaxel
2
Cisplatin
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
taxane
1
liposomal doxorubicin
1
durvalumab
1
cemiplimab
1
atezolizumab
1
Sorafenib
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Irinotecan
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Drug Therapy
1
Biosimilar Pharmaceuticals
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Vaccinia
×
Sorafenib
×
Clear all
NCT02562755
2020-12-16
PHOCUS
SillaJen, Inc.
Phase 3
Completed
459 enrolled
12 charts